Why is There So Much Attention on Obesity Drugs?
High U.S. prices and demand for Ozempic and Wegovy have implications for insurance premiums, public program costs, and affordability.
Search
-
-
KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
FeatureKFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.
-
As COVID-19 Divisions, Attacks, and Misinformation Take Their Toll, Less Than Half of the Public Is Confident That the CDC and FDA Can Carry Out Core Functions
News ReleaseFive years after the start of COVID-19 pandemic and the communications challenges, divisions, and false claims that followed, less than half of the public say they have at least some confidence in the federal government’s health agencies like the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) to carry…
-
Most People in the Most Rural Counties Get Medicare Coverage from Traditional Medicare
Issue BriefWhile enrollment in Medicare Advantage, the private plan alternative to traditional Medicare, has grown steadily over the past decade, traditional Medicare remains the most common source of coverage for people who live in rural areas.
-
How Does Medical Inflation Compare to Inflation in the Rest of the Economy?
Issue BriefThis brief analyzes prices for medical care compared to other goods and services using consumer price index (CPI) and producer price index (PPI) data. Overall prices grew by 3.5% in March 2024 from the previous year, while prices for medical care increased by only 2.2%.
-
What is Medicaid Estate Recovery?
Issue BriefUnder estate recovery, state Medicaid programs are required to recover the costs of long-term care and related hospital and prescription drug services for enrollees ages 55 and older. KFF examines the wide variation in estate recovery practices across states as well as the criticisms of this policy, which have led to federal proposals to modify or reduce it.
-
The Facts About the $35 Insulin Copay Cap in Medicare
Policy WatchThis brief describes the facts about actions taken under both the Trump and Biden Administrations related to capping insulin copayments for people with Medicare and explains the differences between their approaches.
-
The Impact of H.R. 1 on Two Medicaid Eligibility Rules
Issue BriefThis issue brief describes the impact of H.R.1's 10-year delay in implementing provisions in two Medicaid eligibility rules that would have reduced red tape. The delayed rules are projected to decrease federal spending and future Medicaid and CHIP enrollment and increase coverage loss.
-
Coverage of Sexual and Reproductive Health Services in Medicare
Issue BriefThis brief describes Medicare coverage of sexual and reproductive health services, including contraception, and compares that coverage with private insurance plans and Medicaid. These benefits are particularly relevant to nearly 1 million women of reproductive age (20-49) who are eligible for Medicare due to having a long-term disability.
-
FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program
Issue BriefThe Centers for Medicare & Medicaid Services (CMS) recently announced the drugs selected for the second round of negotiation for the Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and CMS's implementation of the program, with a focus on the details that apply for 2027, the second year that negotiated prices will be available under the program.